Tag: ASX: PAB)
BioCina launches manufacturing program for Patrys’ injectable delirium therapy
BioCina Pty Ltd, a global Contract Development and Manufacturing Organisation (CDMO), has launched a comprehensive manufacturing program for RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care.
Featured Article
AMCA Impact Study highlights AI’s role in improving HVAC safety compliance
A new AMCA Impact Study has highlighted the growing challenge of helping HVAC contractors access reliable safety and compliance information quickly, particularly for small and medium-sized businesses operating in Australia's highly regulated construction environment.
